Figure 4 Flow chart of the MDS MSA Study Group aims

Slides:

Advertisements

Similar presentations

Table 3 Limb-girdle muscular dystrophy standardized data collection form and HPO mapping Thompson, R. & Straub, V. et al. (2016) Limb-girdle muscular dystrophies.

Advertisements

Nat. Rev. Neurol. doi:10/1038/nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 4 Progression-free survival, according to treatment group

Figure 3 Life expectancy at birth in all countries included

Figure 2 The US Centers for Disease Control and

Figure 4 Time course of the development of physiological changes

Figure 4 Host damage from infection-related inflammatory

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Overview of risk factors for Parkinson disease dementia

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 General framework of brain–computer interface (BCI) systems

Figure 2 The new concept of prodromal RBD

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Proportion of patients for whom NEDA

Figure 5 Number of AHSCT procedures for

Figure 4 Neuromyelitis optica spectrum disorder brain lesions

Figure 4 Brainstem lesions and acute central vestibular syndrome

Figure 2 Common peripheral vestibular disorders

Figure 5 Corticosteroid treatment can reduce brain

Figure 1 Diagnostic tiers of Parkinson disease as single disease

Figure 3 Translational research projects in LGMD

Figure 1 Allele frequency and effect size for ALS-associated genes

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Poststroke plasticity and recovery

Figure 2 Precision medicine based on a network approach

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Cardiol. doi: /nrcardio

Figure 5 High cervical spinal cord stimulators

Figure 1 Clinical correlates of neurodegeneration in MS

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Genetic pleiotropy in ALS

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Evolution of multiple sclerosis

Figure 1 Zika virus transmission and clinical syndromes

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Anatomical patterns of neuropathy

Figure 1 Proportional motor recovery in the upper limb

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Diagnostic scheme for MSA

Figure 3 Stroke-related deaths and DALYs by country development status

Figure 2 Age-specific prevalence of common comorbidities

Figure 2 Carotid artery inflammation detected using 68Ga-DOTATATE-PET

Figure 1 Key events in the pathophysiological cascade of MSA

Figure 6 Combining population-wide and high-risk strategies

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Frequency of vertigo and dizziness syndromes

Figure 2 Logistical requirements for autologous

Figure 3 Potential interplay between physiological

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Chromosomal region 15q11.2–q13

Figure 1 Clinical aspects of LGMD subtypes

Figure 1 Tau PET images in patients with Alzheimer disease

Figure 2 Title page of An Essay on the Shaking Palsy

Figure 3 Overall survival, according to treatment group

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Timing of the effects of deep brain stimulation

Figure 1 Endovascular treatment in acute ischaemic stroke

Figure 1 A large number of genes are potentially associated with CIPN

Nat. Rev. Neurol. doi: /nrneurol

Figure 4 Jean-Martin Charcot (1825–1893)

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 A case of early-onset PSD

Figure 2 Network connections of the hypothalamus

Diagnosis and Management of Headache in Older Adults

18F-dopa positron emission tomography (PET) in a normal subject, a patient with idiopathic Parkinson's disease (PD), and a patient with multiple system.

Defining diagnostic brain MRI markers in early MSA

Presentation transcript:

Figure 4 Flow chart of the MDS MSA Study Group aims Figure 4 | Flow chart of the MDS MSA Study Group aims. The work programme of the International Parkinson and Movement Disorders Society multiple system atrophy (MDS MSA) Study Group is split into two parts: a basic and clinical research part and an educational part. Several work packages were developed in view of the ultimate goal: the development of novel therapies for patients with MSA. Krismer, F. & Wenning, G. K. (2017) Multiple system atrophy: insights into a rare and debilitating movement disorder Nat. Rev. Neurol. doi:10.1038/nrneurol.2017.26